Regeneron’s investigational siRNA therapeutic, cemdisiran, met both the primary endpoint and key secondary endpoints in the Phase 3 NIMBLE trial for generalized myasthenia gravis (gMG). The study enrolled 123 patients in the primary analysis—64 received cemdisiran and 59 received placebo—and demonstrated a 4.5‑point improvement in the MG‑ADL total score versus a 2.2‑point improvement for placebo, yielding a placebo‑adjusted gain of 2.3 points. The benefit was sustained through 24 weeks, the longest follow‑up period reported for any gMG therapy to date.
The safety profile was favorable. No serious infections or deaths were reported during the double‑blind, placebo‑controlled treatment period. A single death due to pneumonia occurred in the extension phase in a patient with comorbidities, but it was not attributed to the study drug. Cemdisiran is administered every 12 weeks, offering a convenient dosing schedule compared with many current gMG therapies that require more frequent administration.
Regeneron filed a U.S. regulatory application for cemdisiran in the first quarter of 2026 and plans additional filings in the European Union. The positive Phase 3 data support the company’s strategy to diversify beyond its established ophthalmology and immunology franchises, positioning cemdisiran as a potential new revenue driver once FDA approval is obtained. The trial’s success also marks the first time a siRNA therapy has achieved such outcomes in a chronic autoimmune neuromuscular disease, underscoring the therapeutic promise of Regeneron’s proprietary VelociSuite® platform.
Financially, Regeneron reported Q1 2025 revenues of $3.0 billion with GAAP diluted EPS of $7.27, compared with $3.15 billion and $6.27 in Q1 2024. The company’s upcoming Q1 2026 earnings, scheduled for April 29 2026, are expected to reach $3.4479 billion in revenue and $9.10 in EPS, reflecting continued growth in core segments and the impact of the new cemdisiran pipeline. The company also anticipates an acquired in‑process R&D charge of approximately $102 million in Q1 2026, which is projected to reduce GAAP and non‑GAAP diluted EPS by about $0.81 for the quarter.
Management highlighted the unmet need for rapid, sustained efficacy with reduced treatment burden in gMG. “The trial demonstrates that a single siRNA therapeutic can provide durable benefit with a convenient dosing schedule,” said a Regeneron spokesperson. The results reinforce Regeneron's commitment to translating its scientific innovations into medicines that address significant patient needs and expand its portfolio beyond its traditional therapeutic areas.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.